Disc Medicine Inc.
$ 77.44
0.00%
07 Aug - close price
- Market Cap 2,973,142,000 USD
- Current Price $ 77.44
- High / Low $ 78.79 / 76.78
- Stock P/E N/A
- Book Value 16.80
- EPS -6.59
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.39 %
- 52 Week High 99.50
- 52 Week Low 40.00
About
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$101.17
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-30 | 2026-05-05 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-27 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-03-21 | 2023-11-09 |
| Reported EPS | -1.54 | -1.65 | -1.62 | -1.77 | -1.58 | -1.02 | -0.98 | -0.89 | -1.03 | -1.09 | -0.9 | -0.58 |
| Estimated EPS | -1.58 | -1.73 | -1.69 | -1.46 | -1.17 | -1.07 | -1.1036 | -1.05 | -1.1 | -0.99 | -0.78 | -0.8 |
| Surprise | 0.04 | 0.08 | 0.07 | -0.31 | -0.41 | 0.05 | 0.1236 | 0.16 | 0.07 | -0.1 | -0.12 | 0.22 |
| Surprise Percentage | 2.5316% | 4.6243% | 4.142% | -21.2329% | -35.0427% | 4.6729% | 11.1997% | 15.2381% | 6.3636% | -10.101% | -15.3846% | 27.5% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IRON
2026-08-07 23:41:02
Disc Medicine insider Rahul Khara sold 5,000 shares of the company's stock for $400,000, reducing his direct ownership by 8.72% to 52,324 shares. The company recently reported a quarterly loss of $1.54 per share, beating analyst expectations, and has a "Moderate Buy" consensus rating with an average price target of $106.00. Institutional investors hold approximately 83.7% of the company's stock.
2026-08-07 22:41:02
Rahul Khara, Chief Legal Officer at Disc Medicine Inc. (IRON), sold 5,000 shares worth $400,000 on August 6, 2026, while also acquiring 5,000 shares through stock option exercise for $73,450. These transactions were part of a Rule 10b5-1 trading plan. Following these sales, Khara directly holds 52,324 shares and beneficially owns additional derivative securities.
2026-08-07 21:41:02
Disc Medicine, Inc.'s Chief Legal Officer, Rahul Khara, exercised 5,000 stock options at $14.69 per share and subsequently sold 5,000 common shares at $80.00 per share on August 6, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 19, 2026. Following these transactions, Khara retains 49,804 unexercised options and 52,324 common shares.
2026-08-06 20:40:15
An IRON insider has filed a Form 144 notice to sell 5,000 shares of common stock, valued at $394,550.00, on August 6, 2026. This sale follows the exercise of stock options for cash on the same date. The filing also details previous Rule 10b5-1 sales by Rahul Khara, totaling 10,000 shares over three transactions in June 2026.
2026-08-06 16:41:02
H.C. Wainwright has reiterated its Buy rating on Disc Medicine (IRON.US) and set a target price of $120. This indicates a strong positive outlook from the firm regarding the company's stock performance.
2026-08-06 14:12:17
FMR LLC and Abigail P. Johnson have reported an updated beneficial ownership of 12.8% of Disc Medicine Inc. (IRON) common stock, totaling 4,875,472.97 shares, through an Amendment No. 4 to a Schedule 13G filing. FMR LLC holds sole voting power over 4,875,263 shares and sole dispositive power over all 4,875,472.97 shares, while Abigail P. Johnson has sole dispositive power over the same amount but no voting power. The filing confirms that other persons may receive dividends or sale proceeds, but none hold more than a 5% interest individually.
